First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer.

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is a validated treatment option for patients with advanced prostate cancer. Although PSMA expression is not limited to prostate tissue, little is known about its relevance to other types of cancer. Here, we present a case report of a patient with uterine leiomyosarcoma that is progressing while on immunotherapy and treated with 177Lu-PSMA radionuclide therapy. We report for the first time that 177Lu-PSMA radionuclide therapy combined with immunotherapy outside of prostate cancer. We did observe post-treatment reduction of tumor growth rate, although we did not notice disease response based on RECIST criteria. We suggest that 177Lu-PSMA treatment especially combined with immunotherapy may be an option for patients with cancer without other therapeutic options. Insights: 177Lu-PSMA radionuclide therapy should be considered for any tumor stained positive for PSMA.

Journal for immunotherapy of cancer. 2022 Oct [Epub]

Antonia Digklia, Sarah Boughdad, Krisztian Homicsko, Clarisse Dromain, Mounir Trimech, Ana Dolcan, Solange Peters, John Prior, Niklaus Schaefer

Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland ., Nuclear Medicine and Molecular Imaging, University of Lausanne, Lausanne, Switzerland., Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., University of Lausanne, Lausanne, Switzerland., Sarcoma Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

email news signup